Medscape is available in 5 Language Editions – Choose your Edition here.


Rh Incompatibility

  • Author: Leon Salem, MD, MS; Chief Editor: Pamela L Dyne, MD  more...
Updated: Feb 07, 2014


The Rh factor (ie, Rhesus factor) is a red blood cell surface antigen that was named after the monkeys in which it was first discovered. Rh incompatibility, also known as Rh disease, is a condition that occurs when a woman with Rh-negative blood type is exposed to Rh-positive blood cells, leading to the development of Rh antibodies.

Rh incompatibility can occur by 2 main mechanisms. The most common type occurs when an Rh-negative pregnant mother is exposed to Rh-positive fetal red blood cells secondary to fetomaternal hemorrhage during the course of pregnancy from spontaneous or induced abortion, trauma,[1] invasive obstetric procedures, or normal delivery. Rh incompatibility can also occur when an Rh-negative female receives an Rh-positive blood transfusion. In part, this is the reason that blood banks prefer using blood type "O negative" or "type O, Rh negative," as the universal donor type in emergency situations when there is no time to type and crossmatch blood.

The most common cause of Rh incompatibility is exposure from an Rh-negative mother by Rh-positive fetal blood during pregnancy or delivery. As a consequence, blood from the fetal circulation may leak into the maternal circulation, and, after a significant exposure, sensitization occurs leading to maternal antibody production against the foreign Rh antigen.

Once produced, maternal Rh immunoglobulin G (IgG) antibodies may cross freely from the placenta to the fetal circulation, where they form antigen-antibody complexes with Rh-positive fetal erythrocytes and eventually are destroyed, resulting in a fetal alloimmune-induced hemolytic anemia.[2] Although the Rh blood group systems consist of several antigens (eg, D, C, c, E, e), the D antigen is the most immunogenic; therefore, it most commonly is involved in Rh incompatibility.

Recommendations for screening for Rh incompatibility are available from the US Preventive Services Task Force.[3]



The amount of fetal blood necessary to produce Rh incompatibility varies. In one study, less than 1 mL of Rh-positive blood was shown to sensitize volunteers with Rh-negative blood. Conversely, other studies have suggested that 30% of persons with Rh-negative blood never develop Rh incompatibility, even when challenged with large volumes of Rh-positive blood. Once sensitized, it takes approximately one month for Rh antibodies in the maternal circulation to equilibrate in the fetal circulation. In 90% of cases, sensitization occurs during delivery. Therefore, most firstborn infants with Rh-positive blood type are not affected because the short period from first exposure of Rh-positive fetal erythrocytes to the birth of the infant is insufficient to produce a significant maternal IgG antibody response.

The risk and severity of sensitization response increases with each subsequent pregnancy involving a fetus with Rh-positive blood. In women who are prone to Rh incompatibility, the second pregnancy with an Rh-positive fetus often produces a mildly anemic infant, whereas succeeding pregnancies produce more seriously affected infants who ultimately may die in utero from massive antibody-induced hemolytic anemia.

Risk of sensitization depends largely upon the following 3 factors:

  1. Volume of transplacental hemorrhage
  2. Extent of the maternal immune response
  3. Concurrent presence of ABO incompatibility

The incidence of Rh incompatibility in the Rh-negative mother who is also ABO incompatible is reduced dramatically to 1-2% and is believed to occur because the mother's serum contains antibodies against the ABO blood group of the fetus. The few fetal red blood cells that are mixed with the maternal circulation are destroyed before Rh sensitization can proceed to a significant extent. Fortunately, ABO incompatibility usually does not cause serious sequela.

Rh incompatibility is only of medical concern for females who are pregnant or plan to have children in the future. Rh-positive antibodies circulating in the bloodstream of an Rh-negative woman otherwise have no adverse effects.




United States

Only 15% of the population lack the Rh erythrocyte surface antigen and are considered Rh-negative. The vast majority (85%) of individuals are considered Rh positive. Rh sensitization occurs in approximately 1 per 1000 births to women who are Rh negative. The Southwest United States has an incidence approximately 1.5 times the national average, which likely is caused by immigration factors and limited access to medical care since blood typing is a routine part of prenatal care. Even so, only 17% of pregnant women with Rh-negative blood who are exposed to Rh-positive fetal blood cells ever develop Rh antibodies.


During the course of Rh incompatibility, the fetus is primarily affected. The binding of maternal Rh antibodies produced after sensitization with fetal Rh-positive erythrocytes results in fetal autoimmune hemolysis. As a consequence, large amounts of bilirubin are produced from the breakdown of fetal hemoglobin and are transferred via the placenta to the mother where they are subsequently conjugated and excreted by the mother. However, once delivered, low levels of glucuronyl transferase in the infant preclude the conjugation of large amounts of bilirubin and may result in dangerously elevated levels of serum bilirubin and severe jaundice.

Mildly affected infants may have little or no anemia and may exhibit only hyperbilirubinemia secondary to the continuing hemolytic effect of Rh antibodies that have crossed the placenta.

Moderately affected infants may have a combination of anemia and hyperbilirubinemia/jaundice.

In severe cases of fetal hyperbilirubinemia, kernicterus develops. Kernicterus is a neurologic syndrome caused by deposition of bilirubin into central nervous system tissues. Kernicterus usually occurs several days after delivery and is characterized by loss of the Moro (ie, startle) reflex, posturing, poor feeding, inactivity, a bulging fontanelle, a high-pitched shrill cry, and seizures. Infants who survive kernicterus may go on to develop hypotonia, hearing loss, and mental retardation.

Another serious life-threatening condition observed in infants affected by Rh incompatibility is erythroblastosis fetalis, which is characterized by severe hemolytic anemia and jaundice. The most severe form of erythroblastosis fetalis is hydrops fetalis, which is characterized by high output cardiac failure, edema, ascites, pericardial effusion, and extramedullary hematopoiesis. Newborns with hydrops fetalis are extremely pale with hematocrits usually less than 5. Hydrops fetalis often results in death of the infant shortly before or after delivery and requires an emergent exchange transfusion if there is to be any chance of infant survival.


Emergent delivery of an infant with hydrops fetalis should be as nontraumatic as possible. Ideally, a neonatologist who is prepared to perform an exchange transfusion should attend to the infant immediately.[4]


Approximately 15-20% of white patients, as opposed to 5-10% of black patients, have the Rh-negative blood type.

Among individuals of Chinese and American Indian descent, the incidence of Rh-negative blood type is less than 5%.

Contributor Information and Disclosures

Leon Salem, MD, MS Associate Attending Physician, Kaiser Permanente, Southern California

Leon Salem, MD, MS is a member of the following medical societies: American College of Emergency Physicians

Disclosure: Nothing to disclose.


Karen R Singer, PA-C Physician Assistant, Department of Pediatrics, Fountain Valley Medical Center, South Counties Pediatric Critical Care Medical Group, Fountain Valley and Long Beach, California

Karen R Singer, PA-C is a member of the following medical societies: American Academy of Physician Assistants

Disclosure: Nothing to disclose.

Specialty Editor Board

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

John G Pierce, Jr, MD Associate Professor, Departments of Obstetrics/Gynecology and Internal Medicine, Medical College of Virginia at Virginia Commonwealth University

John G Pierce, Jr, MD is a member of the following medical societies: American College of Obstetricians and Gynecologists, Association of Professors of Gynecology and Obstetrics, Christian Medical and Dental Associations, Medical Society of Virginia, Society of Laparoendoscopic Surgeons

Disclosure: Nothing to disclose.

Chief Editor

Pamela L Dyne, MD Professor of Clinical Medicine/Emergency Medicine, University of California, Los Angeles, David Geffen School of Medicine; Attending Physician, Department of Emergency Medicine, Olive View-UCLA Medical Center

Pamela L Dyne, MD is a member of the following medical societies: American Academy of Emergency Medicine, American College of Emergency Physicians, Society for Academic Emergency Medicine

Disclosure: Nothing to disclose.

Additional Contributors

Assaad J Sayah, MD, FACEP Chief, Department of Emergency Medicine; Senior Vice President, Primary and Emergency Care, Cambridge Health Alliance

Assaad J Sayah, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians, Massachusetts Medical Society, National Association of EMS Physicians

Disclosure: Nothing to disclose.

  1. Thorp JM. Utilization of anti-RhD in the emergency department after blunt trauma. Obstet Gynecol Surv. 2008 Feb. 63(2):112-5. [Medline].

  2. Elalfy MS, Elbarbary NS, Abaza HW. Early intravenous immunoglobin (two-dose regimen) in the management of severe Rh hemolytic disease of newborn--a prospective randomized controlled trial. Eur J Pediatr. 2011 Apr. 170(4):461-7. [Medline].

  3. [Guideline] US Preventive Services Task Force. Screening for Rh(D) incompatibility: recommendation statement. Rockville (MD): Agency for Healthcare Research and Quality (AHRQ). 2004. [Full Text].

  4. McMahan MJ, Donovan EF. The delivery room resuscitation of the hydropic neonate. Semin Perinatol. 1995 Dec. 19(6):474-82. [Medline].

  5. Cardo L, Garcia BP, Alvarez FV. Non-invasive fetal RHD genotyping in the first trimester of pregnancy. Clin Chem Lab Med. 2010 Aug. 48(8):1121-6. [Medline].

  6. Kolialexi A, Tounta G, Mavrou A. Noninvasive fetal RhD genotyping from maternal blood. Expert Rev Mol Diagn. 2010 Apr. 10(3):285-96. [Medline].

  7. Herold TJ, Whittaker DS, Glynn T. Determining the accuracy of a rapid point-of-care test for determining Rh(D) phenotype. Acad Emerg Med. 2005 May. 12(5):474-6. [Medline].

  8. Agre P, Smith BL, Hartel-Schenk S. Biochemistry of the erythrocyte Rh polypeptides: a review. Yale J Biol Med. 1990 Sep-Oct. 63(5):461-7. [Medline].

  9. American College of Obstetricians and Gynecologists. Management of isoimmunization in pregnancy. ACOG Technical Bulletin 148. 1990.

  10. American College of Obstetricians and Gynecologists. Prevention of D isoimmunization. ACOG Technical Bulletin 147. 1990.

  11. Bowman JM. Hemolytic disease (erythroblastosis fetalis). Maternal-Fetal Medicine: Principles and Practice. 2nd ed. Philadelphia, Pa: WB Saunders; 1989. 613-655.

  12. Copel JA, Gollin YG, Grannum PA. Alloimmune disorders and pregnancy. Semin Perinatol. 1991 Jun. 15(3):251-6. [Medline].

  13. Daffos F, Capella-Pavlovsky M, Forestier F. Fetal blood sampling via the umbilical cord using a needle guided by ultrasound. Report of 66 cases. Prenat Diagn. 1983 Oct. 3(4):271-7. [Medline].

  14. Grant J, Hyslop M. Underutilization of Rh prophylaxis in the emergency department: a retrospective survey. Ann Emerg Med. 1992 Feb. 21(2):181-3. [Medline].

  15. Issitt PD. Race-related red cell alloantibody problems. Br J Biomed Sci. 1994 Jun. 51(2):158-67. [Medline].

  16. Kleihauer E, Braun H, Betke K. Demonstation von fetalem Haemoglobin in den Erythrozyten eines Blutausstrichs. Klin Wochenschr. 1957. 35:637-8.

  17. Mourant AE, Kopec AC, Domaniewska-Sobczak K. The Distribution of the Human Blood Groups and Other Biochemical Polymorphisms. 2nd ed. London, England: Oxford University Press; 1976.

  18. Peterec SM. Management of neonatal Rh disease. Clin Perinatol. 1995 Sep. 22(3):561-92. [Medline].

  19. Reece EA, Copel JA, Scioscia AL, Grannum PA, DeGennaro N, Hobbins JC. Diagnostic fetal umbilical blood sampling in the management of isoimmunization. Am J Obstet Gynecol. 1988 Nov. 159(5):1057-62. [Medline].

  20. Selinger M. Immunoprophylaxis for rhesus disease--expensive but worth it?. Br J Obstet Gynaecol. 1991 Jun. 98(6):509-12. [Medline].

  21. Walker RH. American Association of Blood Banks Technical Manual. 11th ed. Bethesda, Md: AABB; 1993.

All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.